Evidence map›Paper›PMID 24025770›Full record

ArticleNature2013

Immune clearance of highly pathogenic SIV infection.

Scott G Hansen, Michael Piatak, Abigail B Ventura, Colette M Hughes, Roxanne M Gilbride, Julia C Ford, Kelli Oswald, Rebecca Shoemaker, Yuan Li, Matthew S Lewis and 16 more

Erratum issuedAbstract read
In one paragraph

Article in Nature, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 417 papers.

0numbers the graph read from it
0cells of the map it votes in
417citing papers in PubMed
33.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

417 citing papers in PubMed, 615 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Antigenic competition in CD4Science translational medicine · 2019
    Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

357 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

26 authors at 4 institutions in 2 countries.

Scott G HansenVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon 97006, USA.
Michael Piatak
Abigail B Ventura
Colette M Hughes
Roxanne M Gilbride
Julia C Ford
Kelli Oswald
Rebecca Shoemaker
Yuan Li
Matthew S Lewis
Awbrey N Gilliam
Guangwu Xu
Nathan Whizin
Benjamin J Burwitz
Shannon L Planer
John M Turner
Alfred W Legasse
Michael K Axthelm
Jay A Nelson
Klaus Früh
Jonah B Sacha
Jacob D Estes
Brandon F Keele
Paul T Edlefsen
Jeffrey D Lifson
Louis J Picker
Oregon Health & Science University · USScience Applications International Corporation (United States) · USOregon National Primate Research Center · USFred Hutch Cancer Center · US

Funding

Upgrade of confocal microscopy at the Oregon National Primate Research CenterP51OD011092 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI Bonnie J. Nagel · 2012 to 2026
$203.9M
VirologyU19AI095985 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI JOHNSON, R. PAUL · 2011 to 2015
$35.9M
Viral reservoirs and sanctuaries in HAART - treated patients: role and mechanismsU19AI096109 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SCHACKER, TIMOTHY W · 2011 to 2015
$29.5M
Virology and Immunology MonitoringP01AI094417 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI KAHL, CHRISTOPH ADRIAN · 2011 to 2016
$20.5M
Role of Memory T Cell Dynamics in SIV InfectionR37AI054292 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI PICKER, LOUIS J. · 2008 to 2017
$9.8M
Viral Testing CoreU42OD010426 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI Andrew Haertel, Lauren Drew Martin · 2013 to 2026
$6.0M
Efficacy of Oral CMV/SIV VectorsR01DE021291 · NIDCR · OREGON HEALTH & SCIENCE UNIVERSITY · PI PICKER, LOUIS J. · 2011 to 2015
$4.6M
Development of RhCMV Vectors for SIV InfectionR01AI060392 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI PICKER, LOUIS J. · 2004 to 2009
$3.7M
Establishment of Specific Free Rhesus and Pigtail Macques ColoniesU24OD010850 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI AXTHELM, MICHAEL K · 2012 to 2015
$2.7M
CCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001ENIAID NIH HHS P01 AI094417NIAID NIH HHS R01 AI060392NIAID NIH HHS R37 AI054292NIAID NIH HHS U19 AI095985NIAID NIH HHS U19 AI096109NIDCR NIH HHS R01 DE021291NIH HHS P51 OD011092NIH HHS P51OD011092NIH HHS U24 OD010850NIH HHS U42 OD010426
6 · The paper itself

Abstract

Established infections with the human and simian immunodeficiency viruses (HIV and SIV, respectively) are thought to be permanent with even the most effective immune responses and antiretroviral therapies only able to control, but not clear, these infections. Whether the residual virus that maintains these infections is vulnerable to clearance is a question of central importance to the future management of millions of HIV-infected individuals. We recently reported that approximately 50% of rhesus macaques (RM; Macaca mulatta) vaccinated with SIV protein-expressing rhesus cytomegalovirus (RhCMV/SIV) vectors manifest durable, aviraemic control of infection with the highly pathogenic strain SIVmac239 (ref. 5). Here we show that regardless of the route of challenge, RhCMV/SIV vector-elicited immune responses control SIVmac239 after demonstrable lymphatic and haematogenous viral dissemination, and that replication-competent SIV persists in several sites for weeks to months. Over time, however, protected RM lost signs of SIV infection, showing a consistent lack of measurable plasma- or tissue-associated virus using ultrasensitive assays, and a loss of T-cell reactivity to SIV determinants not in the vaccine. Extensive ultrasensitive quantitative PCR and quantitative PCR with reverse transcription analyses of tissues from RhCMV/SIV vector-protected RM necropsied 69-172 weeks after challenge did not detect SIV RNA or DNA sequences above background levels, and replication-competent SIV was not detected in these RM by extensive co-culture analysis of tissues or by adoptive transfer of 60 million haematolymphoid cells to naive RM. These data provide compelling evidence for progressive clearance of a pathogenic lentiviral infection, and suggest that some lentiviral reservoirs may be susceptible to the continuous effector memory T-cell-mediated immune surveillance elicited and maintained by cytomegalovirus vectors.

Indexed as

AnimalsCytomegalovirusFemaleMacaca mulattaMaleMolecular Sequence DataSAIDS VaccinesSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusTime FactorsVaccines, AttenuatedViral LoadVirus ReplicationSAIDS VaccinesVaccines, Attenuated

Identifiers

PMID24025770
PMCPMC3849456
OpenAlexW2028518212

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.